How cell stress responses affect recovery after spinal cord injury
Cell type-specific effects of the integrated stress response pathway after traumatic spinal cord injury
Researchers are looking at how cells' stress response after a traumatic spinal cord injury affects nerve damage, scarring, and inflammation in adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11330629 on NIH RePORTER |
What this research studies
This project studies how different cell types in the injured spinal cord—such as myelin-producing oligodendrocytes, resident microglia, and incoming macrophages—react through a process called the integrated stress response (ISR). The team uses laboratory models, tissue studies, and genetic or molecular tools to track key stress proteins (for example eIF2α, ATF4, CHOP, and the HRI kinase) and to see how prolonged ISR leads to cell death and harmful inflammation that worsens white-matter damage. By reducing or modifying parts of the ISR in these models, investigators look for ways to preserve oligodendrocytes and axons and limit secondary damage. The goal is to identify molecular targets that could lead to therapies to protect tissue and improve function after traumatic spinal cord injury.
Who could benefit from this research
Good fit: Adults (age 21 and over) with recent traumatic spinal cord injury would be the most relevant candidates if the team seeks patient samples or plans future clinical testing.
Not a fit: People with long-standing (chronic) spinal cord injuries or those without traumatic spinal cord injury are unlikely to see direct benefit in the short term.
Why it matters
Potential benefit: If successful, this work could point to new treatments that protect nerve cells, reduce damaging inflammation, and improve recovery after spinal cord injury.
How similar studies have performed: Previous laboratory and animal work shows that blocking parts of the ISR (for example removing CHOP) can protect oligodendrocytes and improve recovery, but moving these findings into human treatments is still early.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Hetman, Michal — University of Louisville
- Study coordinator: Hetman, Michal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.